I believe in continuous growth of this stock. Strongly undervalued. ORBIT-3 and ORBIT-4 Estimated Primary Completion Date: July 2016 https://clinicaltrials.gov/ct2/show/NCT02104245?term=aradigm&rank=1 https://clinicaltrials.gov/ct2/show/NCT01515007?term=aradigm&rank=2